Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia
Calquence demonstrated superior progression-free survival and favourable tolerability in both previously untreated and relapsed or refractory patientsAstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The approval by the European Commission was based on positive results from two Phase III clinical trials, ELEVATE-TN in patients with previously untreated CLL and